NAMPT is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-16. Numbers and descriptions here follow the published literature rather than marketing material.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
| Property | Value | Notes |
|---|---|---|
| Chemical name | beta-Nicotinamide mononucleotide | Free acid and salt forms share the core structure. |
| Molecular formula | C11H15N2O8P | Calculated for the free acid; salt forms add counterions. |
| Molar mass | 334.22 g/mol | Approximate value for the free acid form. |
| Appearance | White to off-white powder | Color and texture can vary with purity and salt form. |
| Solubility | Water-soluble | Typically soluble in aqueous media; less soluble in nonpolar solvents. |
Trace amounts of NMN have been reported in certain plant foods, including edamame, avocado, broccoli, cucumber, and cabbage. Reported concentrations vary widely because analytical methods differ and food matrices complicate extraction. Endogenous production in cells is generally considered more quantitatively important than dietary intake, though precise human turnover rates are difficult to establish. Commercial NMN for research or consumer products is commonly made through enzymatic synthesis or chemical phosphorylation routes. Regulatory classification differs by country; in some jurisdictions NMN is sold as a supplement, while in others it is treated as a novel food ingredient or restricted substance.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. As an intermediate in the NAD+ salvage pathway, NMN is converted to nicotinamide adenine dinucleotide, a coenzyme central to cellular redox reactions. NAD+ also serves as a substrate for enzymes involved in DNA repair, stress responses, and metabolic regulation. The compound is therefore part of normal cellular biochemistry rather than an exclusively synthetic molecule.
Two enzymatic steps define the canonical route from nicotinamide to NAD+. Nicotinamide phosphoribosyltransferase, known as NAMPT, produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN adenylyltransferases, or NMNAT enzymes, then couple NMN with ATP to form NAD+. Whether intact NMN crosses cell membranes efficiently remains an active area of investigation; some studies propose direct transport, while others emphasize extracellular dephosphorylation to nicotinamide riboside followed by uptake. The relative contribution of each route likely depends on cell type, tissue, and experimental conditions.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
== Prevalence == Comorbidity of addictive disorders and other psychiatric disorders, i.e., dual disorders, is very common and a large body of literature has accumulated demonstrating that mental disorders are strongly associated with substance use disorders. Adolescents and young adults are particularly at risk for dual diagnosis, as early substance use can interfere with brain development and exacerbate emerging mental health conditions. The 2011 USA National Survey on Drug Use and Health found that 17.5% of adults with a mental illness had a co-occurring substance use disorder; this works out to 7.98 million people. Estimates of co-occurring disorders in Canada are even higher, with an estimated 40-60% of adults with a severe and persistent mental illness experiencing a substance use disorder in their lifetime. A study by Kessler et al. in the United States attempting to assess the prevalence of dual diagnosis found that 47% of clients with schizophrenia had a substance misuse disorder at some time in their life, and the chances of developing a substance misuse disorder was significantly higher among patients with a psychotic illness than in those without a psychotic illness. Another study looked at the extent of substance misuse in a group of 187 chronically mentally ill patients living in the community. According to the clinician's ratings, around a third of the sample used alcohol, street drugs, or both during the six months before evaluation. Further UK studies have shown slightly more moderate rates of substance misuse among mentally ill individuals.
== Tissue and subcellular distribution == Galectin-7 is found both intracellularly and extracellularly. It is secreted via a non-classical, endoplasmic reticulum–Golgi–independent pathway and can form galectin–glycan lattices by clustering on cell-surface receptors. It is also present in primary cilia of epithelial cell types such as those of the airway and kidney.
=== First confirmed cases: May–June 2022 === On 12 May 2022, the North Korean government declared a "severe national emergency", after samples from an unspecified number of people tested positive for COVID-19. This marked the first time that North Korea had publicly acknowledged the existence of COVID-19 cases in the country. The Korean Central News Agency stated that Supreme Leader Kim Jong Un had called an emergency meeting of the Politburo of the Workers' Party of Korea after learning of the samples, which were sourced from residents of Pyongyang and had symptoms "consistent with" the Omicron variant. The Politburo recommended the implementation of a "maximum" emergency quarantine, to include nationwide lockdowns, border restrictions, and restrictions on group sizes in workplaces. During the politburo meeting, the previous anti-pandemic strategy was criticised. NK News reported that the entire country had been placed under a lockdown two days prior, though farmers in border regions close to South Korea were seen still tending the fields. It was later reported by state media that at least one North Korean died after testing positive, and that 187,800 people are now under quarantine due to "fever". On 13 May, Kim Jong Un held a meeting at the State Emergency Epidemic Prevention Headquarters, where he called for further anti-pandemic work, lockdowns, and isolation of suspected cases. The effort to stop the spread was declared to be a supreme task of the party.
=== Expansion and acquisition === By 1997, Reddy's made the transition from being an API and bulk drug supplier to regulated markets like the US and the UK, and a branded formulations supplier in unregulated markets like India and Russia, into producing generics, by filing an Abbreviated New Drug Application (ANDA) in the USA. The same year, Reddy's out-licensed a molecule for clinical trials to Novo Nordisk, a Danish pharmaceutical company. It strengthened its Indian manufacturing operations by acquiring American Remedies Ltd. in 1999. This acquisition made Reddy's the third largest pharmaceutical company in India, after Ranbaxy and Glaxo (I) Ltd., with a full spectrum of pharmaceutical products, which included bulk drugs, intermediates, finished dosages, chemical synthesis, diagnostics and biotechnology. Reddy's also started exploiting Para 4 filing as a strategy in bringing new drugs to the market at a faster pace. In 1999 it submitted a Para 4 application for omeprazole, the drug that had been the cornerstone of its success in India. In December 2000, Reddy's had undertaken its first commercial launch of a generic product in the US, and its first product with market exclusivity was launched there in August 2001. The same year, it also became the first non-Japanese pharmaceutical company from the Asia-Pacific region to obtain a New York Stock Exchange listing. In 2001 Reddy's became the first Indian company to launch the generic drug, fluoxetine (a generic version of Eli Lilly and Company’s Prozac) with 180-day market exclusivity in the USA.
Sources: en.wikipedia.org
The magnetron method: Using a GRD7 Valve (Ferranti valve), electrons are expelled from a hot tungsten-wire filament towards an anode. The electron is then deflected using a solenoid. From the current in the solenoid and the current in the Ferranti Valve, e/m can be calculated. Fine beam tube method: A heater heats a cathode, which emits electrons. The electrons are accelerated through a known potential, so the velocity of the electrons is known. The beam path can be seen when the electrons are accelerated through a helium (He) gas. The collisions between the electrons and the helium gas produce a visible trail. A pair of Helmholtz coils produces a uniform and measurable magnetic field at right angles to the electron beam. This magnetic field deflects the electron beam in a circular path. By measuring the accelerating potential (volts), the current (amps) to the Helmholtz coils, and the radius of the electron beam, e/m can be calculated.
== Research == Selenium disulfide has been suggested to be effective as a treatment for hyperkeratosis based on a small case series of three treated patients. It has also been reported to be effective in the treatment of scalp psoriasis based on clinical observation of over 100 treated patients and two case reports of dramatic response. Selenium sulfide is under development for the treatment of meibomianitis (meibomian gland dysfunction) and dry eyes in topical and ophthalmic formulations. As of March 2021, it is in phase 2/3 clinical trials for meibomianitis and phase 2 trials for dry eyes. The developmental code name of selenium sulfide for these uses is AZR-MD-001 and it is being developed by Azura Ophthalmics.
Critical response to Ellipse was generally positive. At Metacritic, which assigns a normalized rating out of 100 to reviews from mainstream critics, the album received an average score of 68, based on 12 reviews. It also earned her a further two Grammy Nominations on 2 December for Best Pop Instrumental Performance for "The Fire" and Best Engineered Non-Classical Album. On 31 January 2010, it was announced that Heap had won the latter award.
The discovery of nuclear fission occurred in 1938 in the buildings of the Kaiser Wilhelm Society for Chemistry, today part of the Free University of Berlin, following over four decades of work on the science of radioactivity and the elaboration of new nuclear physics that described the components of atoms. In 1911, Ernest Rutherford proposed a model of the atom in which a very small, dense and positively charged nucleus of protons was surrounded by orbiting, negatively charged electrons (the Rutherford model). Niels Bohr improved upon this in 1913 by reconciling the quantum behavior of electrons (the Bohr model). In 1928, George Gamow proposed the liquid-drop model, which became essential to understanding the physics of fission. In 1896, Henri Becquerel had found, and Marie Curie named, radioactivity. In 1900, Rutherford and Frederick Soddy, investigating the radioactive gas emanating from thorium, "conveyed the tremendous and inevitable conclusion that the element thorium was slowly and spontaneously transmuting itself into argon gas!" In 1919, following up on an earlier anomaly Ernest Marsden noted in 1915, Rutherford attempted to "break up the atom." Rutherford was able to accomplish the first artificial transmutation of nitrogen into oxygen, using alpha particles directed at nitrogen 14N + α → 17O + p. Rutherford stated, "...we must conclude that the nitrogen atom is disintegrated," while the newspapers stated he had split the atom.
The coat of arms shows a white horse (Saxon Steed) against a red background, which is an old symbol of the Saxon people. Legend has it that the horse was a symbol of the Saxon leader Widukind, albeit a black horse against a yellow background. The colours changed after the Christian baptism of Widukind. White and red are colours (besides black and gold) of the Holy Roman Empire symbolising Christ as the saviour, who is still shown with a red cross against a white background.
Sources: en.wikipedia.org
=== Marketed === Daridorexant (nemorexant; Quviviq) – dual OX1 and OX2 antagonist – approved for insomnia in January 2022, formerly under development for sleep apnea – half-life 8 hours Fazamorexant (Mengping) – dual OX1 and OX2 antagonist – approved for insomnia in China in May 2026 – half-life 2–4 hours Lemborexant (Dayvigo) – dual OX1 and OX2 antagonist – approved for insomnia in December 2019 and released June 1 2020, under development for circadian rhythm sleep disorders, chronic obstructive pulmonary disease, and sleep apnea – half-life 17–55 hours Suvorexant (Belsomra) – dual OX1 and OX2 antagonist – approved for insomnia in August 2014, under development for delirium – half-life 12 hours Vornorexant (Vorzzz) – dual OX1 and OX2 antagonist – approved for insomnia in Japan in August 2025 – half-life 1.5–3 hours
Dylan Thomas was born on 27 October 1914 in Swansea, the son of Florence Hannah (née Williams; 1882–1958), a seamstress, and David John 'Jack' Thomas (1876–1952), a teacher. His father had a first-class honours degree in English from University College, Aberystwyth, and ambitions to rise above his position teaching English literature at the local grammar school. Thomas had one sibling, Nancy Marles (1906–1953), who was eight years his senior. The red-brick, semi-detached house at 5 Cwmdonkin Drive (in the Uplands area), in which Thomas was born and lived until he was 23, had been bought by his parents a few months before his birth. At the 1921 census, Nancy and Dylan are noted as speaking both Welsh and English. Their parents were also bilingual in English and Welsh, and Jack Thomas taught Welsh at evening classes. One of their Swansea relations has recalled that, at home, "Both Auntie Florrie and Uncle Jack always spoke Welsh." There are three accounts from the 1940s of Dylan singing Welsh hymns and songs, and of speaking a little Welsh. Thomas's father chose the name Dylan, which could be translated as "son of the sea" after Dylan ail Don, a character in The Mabinogion. His middle name, Marlais, was given in honour of his great-uncle, William Thomas, a Unitarian minister and poet whose bardic name was Gwilym Marles. The name Dylan being pronounced [ˈdəlan] in Welsh caused his mother to worry that he might be teased as the "dull one". When he broadcast on Welsh BBC early in his career, he was introduced using this pronunciation.
=== Statistics === Southern Rhodesia had contributed more manpower to the Allied cause in World War II, proportional to white population, than any other British dominion or colony, and more than the UK itself. According to figures compiled by MacDonald for his War History of Southern Rhodesia, 26,121 Southern Rhodesians served in the armed forces during the conflict, of whom 2,758 were commissioned officers. Broken down by race and gender, there were 15,153 black men, 9,187 white men, 1,510 white women and 271 coloured and Indian men. Of the 8,390 who served outside the territory, 1,505 were black men, 6,520 were white men, 137 were white women and 228 were coloured or Indian men. According to official figures, 33,145 black Southern Rhodesians were conscripted for labour between 1943 and 1945; Vickery estimates that between 15,000 and 60,000 more may have worked on the aerodromes. According to Ashley Jackson's work The British Empire and the Second World War, the Rhodesian Air Training Group instructed 8,235 Allied pilots, navigators, gunners, ground crew and others—about 5% of overall EATS output. A total of 2,409 Southern Rhodesians (977 officers and 1,432 other ranks) served in the RAF during the war, 373 (86 officers and 287 ratings) joined the Royal Navy, and 13 officers and 36 ratings from Southern Rhodesia mustered into the South African Navy. The vast majority of the rest served in either the Southern Rhodesian territorial forces or the British or South African Army.
Early undiagnosed rheumatic diseases such as preclinical rheumatoid arthritis, early stages of inflammatory spondyloarthritis, polymyalgia rheumatica, myofascial pain syndromes and hypermobility syndrome. Neurological diseases that can have important pain and fatigue components include multiple sclerosis, Parkinson's disease and peripheral neuropathy. Other medical illnesses that should be ruled out are endocrine disease or metabolic disorder (hypothyroidism, hyperparathyroidism, acromegaly, vitamin D deficiency), gastro-intestinal disease (celiac and non-celiac gluten sensitivity), infectious diseases (Lyme disease, hepatitis C and immunodeficiency disease) and the early stages of a malignancy such as multiple myeloma, metastatic cancer and leukemia/lymphoma. Other systemic, inflammatory, endocrine, rheumatic, infectious, and neurologic disorders may cause fibromyalgia-like symptoms, such as systemic lupus erythematosus, Sjögren's disease, ankylosing spondylitis, Ehlers-Danlos syndromes, psoriatic-related polyenthesitis, a nerve compression syndrome (such as carpal tunnel syndrome), and myasthenia gravis. Several medications can evoke pain (statins, aromatase inhibitors, bisphosphonates, and opioids).
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide composed of nicotinamide, ribose, and phosphate. In cells, it is an intermediate in NAD+ biosynthesis.
No, NMN and NAD+ are different molecules. NMN is a precursor that cells can convert into NAD+ through enzymatic steps. NAD+ is a larger dinucleotide that serves as a coenzyme in many reactions.
Nicotinamide riboside, or NR, is another NAD+ precursor but has a different structure. NR lacks the phosphate group present in NMN. Both are studied for their roles in NAD+ metabolism, yet they enter cellular pathways in different ways.
Nicotinamide mononucleotide is a nucleotide intermediate in the biosynthesis of NAD+. It consists of nicotinamide attached to a ribose phosphate unit. NMN occurs naturally in cells and is present at low levels in some foods.